KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2017;32(3):514-522.   Published online 2017 Apr 14     DOI: https://doi.org/10.3904/kjim.2015.299
Citations to this article as recorded by Crossref logo
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
B. Ricciuti, M. Brambilla, A. Cortellini, A. De Giglio, C. Ficorella, A. Sidoni, G. Bellezza, L. Crinò, V. Ludovini, S. Baglivo, G. Metro, R. Chiari
Clinical and Translational Oncology.2019;[Epub]     CrossRef
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Venus Sosa Iglesias, Lorena Giuranno, Ludwig J. Dubois, Jan Theys, Marc Vooijs
Frontiers in Oncology.2018;[Epub]     CrossRef
Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Jacqueline V. Aredo, Sukhmani K. Padda
Current Treatment Options in Oncology.2018;[Epub]     CrossRef
Realities of KRAS-mutated non-small cell lung cancer
Young Joo Min
The Korean Journal of Internal Medicine.2017; 32(3): 442.     CrossRef